세계의 백반증 치료 시장 : 유형별, 치료법별, 최종사용자별, 지역별 예측(-2030년)

Global Vitiligo Treatment Market Research Report Information by Type (Segmental Vitiligo, Non-Segmental Vitiligo), By Treatment (Therapy, Surgery, Medication), By End-User (Hospitals, Ambulatory Clinics, Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)-Forecast till 2030

Market Overview

The Vitiligo Treatment Market industry is anticipated to experience a compound annual growth rate (CAGR) of 6.20% during the forecast period. The market is experiencing growth due to the increasing prevalence of vitligo, the increasing significance of aesthetic appeal and awareness, and the advancements in treatment options.

As a result of the increasing per capita income, the adoption of digital platforms, and the increasing awareness of various aesthetic treatments, there has been a substantial increase in beauty consciousness among consumers in recent years. Between 2015 and 2019, the International Society of Aesthetic Plastic Surgery (ISAPS) reported a 27.3% increase in the global total of non-surgical procedures. Furthermore, the American Society of Plastic Surgeons (ASPS) reported that the number of minimally invasive aesthetic procedures increased by approximately 200% from 2000 to 2017. Additionally, in 2018, approximately 15.9 million minimally invasive cosmetic procedures were conducted, representing a 2% increase from 2017.

Market Segment Insights

Segmental Vitiligo and Non-Segmental Vitiligo comprise the Vitiligo Treatment Market segmentation by Type.

A treatment that encompasses therapy, surgery, and medication is the basis for market segmentation.

The end-user segmentation of the market is based on Hospitals, Ambulatory Clinics, and Others.

Regional Perspectives

The market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World by region. In 2023, the North American Vitiligo Treatment Market held the greatest market share. As a result of the growing awareness of skin disorders and the development of a more sophisticated healthcare infrastructure. Innovative treatments, such as advanced phototherapy, biologics, and topical medications, have been introduced as a result of the region's strong emphasis on research and development.

The market share of the European Vitiligo Treatment Market is anticipated to be the second largest, as a result of the trend toward the integration of Vitiligo Treatment and the favorable health policies. Additionally, the France Vitiligo Treatment Market is anticipated to be the fastest-growing market in the European region, while the German Vitiligo Treatment Market was attributed to holding the largest market share.

From 2024 to 2032, the Asia-Pacific Vitiligo Treatment market is anticipated to experience the most rapid growth. This is the result of improved access to advanced therapies, which is facilitated by rising healthcare expenditures and the improvement of healthcare infrastructure. Additionally, the increasing prevalence of vitiligo and the increasing demand for cosmetic and dermatological remedies are substantial market drivers.

The Middle East, Africa, and Latin America comprise the Rest of the World. The primary factors that are influencing the expansion of Vitiligo Treatment in the Middle East and Africa. The Middle East and Africa region has encountered Increased global awareness and destigmatization of vitiligo are resulting in a higher demand for effective treatments and an increase in the number of diagnoses.

Major Players

Incyte (US), Bausch Health Companies Inc (Canada), Koninklijke Philips N.V. (Netherlands), Reddy's Laboratories Ltd (India), Strata Skin Sciences (US), Clinuvel Pharmaceuticals Ltd (Australia), ISSAR Pharmaceuticals Pvt. Ltd (India), Kernel Medical Equipment CO., LTD (China), LightSources (US), and Roivant Sciences Ltd. (Switzerland) are among the key companies in the Vitiligo Treatment Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 OVERVIEW
  • 1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA MINING
• 3.3 SECONDARY RESEARCH
• 3.4 PRIMARY RESEARCH
  • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 GROWING IMPORTANCE OF THE AESTHETIC APPEAL AND AWARENESS
  • 4.2.2 INCREASING PREVALENCE OF VITLIGO
• 4.3 RESTRAINTS
  • 4.3.1 LACK OF TRAINED PROFESSIONALS
• 4.4 OPPORTUNITIES
  • 4.4.1 RISING NUMBER OF CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 IMPACT OF COVID-19 ON THE VITILIGO TREATMENT MARKET
  • 5.3.1 IMPACT ON SUPPLY CHAIN
  • 5.3.2 IMPACT ON REGION
  • 5.3.3 IMPACT ON DEMAND AND SUPPLY

6 GLOBAL VITILIGO TREATMENT MARKET, BY TYPE

• 6.1 OVERVIEW
• 6.2 SEGMENTAL VITILIGO
• 6.3 NON-SEGMENTAL VITILIGO

7 GLOBAL VITILIGO TREATMENT MARKET, BY TREATMENT TYPE

• 7.1 OVERVIEW
• 7.2 THERAPY
  • 7.2.1 DEPIGMENTATION
  • 7.2.2 LIGHT
• 7.3 SURGERY
  • 7.3.1 SKIN GRAFTING
  • 7.3.2 BLISTER GRAFTING
  • 7.3.3 MICRO-PIGMENTATION
• 7.4 MEDICATION
  • 7.4.1 TOPICAL CORTICOSTEROIDS
  • 7.4.2 IMMUNOSUPPRESSIVE

8 GLOBAL VITILIGO TREATMENT MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS
• 8.3 AMBULATORY CLINICS
• 8.4 OTHERS

9 GLOBAL VITILIGO TREATMENT MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 NORTH AMERICA
  • 9.2.1 US
  • 9.2.2 CANADA
• 9.3 EUROPE
  • 9.3.1 GERMANY
  • 9.3.2 FRANCE
  • 9.3.3 UK
  • 9.3.4 ITALY
  • 9.3.5 SPAIN
  • 9.3.6 REST OF EUROPE
• 9.4 ASIA-PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 JAPAN
  • 9.4.3 INDIA
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA-PACIFIC
• 9.5 REST OF THE WORLD
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA
  • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN VITILIGO TREATMENT MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN VITILIGO TREATMENT MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT APPROVALS/PRODUCT LAUNCHES/DRUG PIPELINE
  • 10.6.2 MERGERS & ACQUISITIONS
• 10.7 MAJOR PLAYERS SALES ANALYSIS
  • 10.7.1 SALES & OPERATING INCOME,
  • 10.7.2 MAJOR PLAYERS R&D ANALYSIS,

11 COMPANY PROFILE

• 11.1 INCYTE
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 BAUSCH HEALTH COMPANIES INC.
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 KONINKLIJKE PHILIPS N.V.
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 DR. REDDY'S LABORATORIES LTD.
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 STRATA SKIN SCIENCES
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 KEY STRATEGIES
• 11.6 CLINUVEL PHARMACEUTICALS LTD
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 ISSAR PHARMACEUTICALS PVT. LTD.
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL ANALYSIS
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 KEY STRATEGIES
• 11.8 KERNEL MEDICAL EQUIPMENT CO., LTD.
  • 11.8.1 COMPANY OVERVIEWS
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 KEY STRATEGIES
• 11.9 LIGHTSOURCES
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL ANALYSIS
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 KEY STRATEGIES
• 11.10 ROIVANT SCIENCES LTD.
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL ANALYSIS
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 PRODUCTS OFFERED
  • 11.10.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS